Key result
Management of NSTEMI during the COVID-19 pandemic was associated with a non-significant trend toward higher in-hospital major cardiovascular events compared to a 2019 historical control.
Why the study?
During the COVID-19 epidemic, conservative medication strategies and reduced invasive procedures for NSTEMI were unavoidable, but whether this strategy impacted in-hospital outcomes remained unclear.
Does management during the COVID-19 pandemic increase in-hospital MACE in NSTEMI patients compared to historical controls?
Cohort (n=260)
No
Does management during the COVID-19 pandemic increase in-hospital MACE in NSTEMI patients compared to historical controls?
The COVID-19 pandemic led to delayed PCI and higher in-hospital adverse event rates for NSTEMI patients, especially those at very high risk.
Answers are grounded in this paper and cite their sources.
Should not change NSTEMI management; leaves open pandemic delay effects in observational data.
BACKGROUND: During coronavirus disease 2019 (COVID-19) epidemic, reducing the number of invasive procedure and choosing conservative medication strategy for patients with non-ST-segment elevation myocardial infarction (NSTEMI) is unavoidable. Whether this relatively conservative strategy will impact in-hospital outcome for NSTEMI patients remains unclear. METHODS AND RESULTS: The current study included all consecutive NSTEMI patients who visited the emergency department in Fuwai Hospital from February 1 to March 31, 2020 and all the NSTEMI patients in the same period of 2019 as a historical control. Very-high-risk patients were defined as clinical presentation of heart failure, cardiac shock, cardiac arrest, recurrent chest pain, and life-threatening arrhythmias. The primary outcome was in-hospital major adverse cardiac events (MACE), defined as a composite of all-cause death, recurrent myocardial infarction, or heart failure. A total of 115 NSTEMI patients were enrolled since the outbreak of COVID-19, and a total of 145 patients were included in the control group. There was a tendency toward higher MACE risk in 2020 compared with 2019 (18.3% vs. 11.7%, p = .14). Among very-high-risk patients, early percutaneous coronary intervention (PCI) strategy in 2019 was associated with reduced MACE risk compared with delayed PCI in 2020 (60.6% [20/33] in 2020 vs. 27.9% [12/43] in 2019, p = .01). CONCLUSIONS: COVID-19 pandemic results in a significant reduction in immediate/early PCI and a trend toward higher adverse event rate during hospitalization, particular in very-high-risk patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2020) conducted a cohort in NSTEMI (n=260). COVID-19 pandemic period (conservative management strategy) vs. Historical control period (2019) was evaluated on In-hospital major adverse cardiac events (MACE), defined as a composite of all-cause death, recurrent myocardial infarction, or heart failure (p=0.14). Management of NSTEMI during the COVID-19 pandemic was associated with a non-significant trend toward higher in-hospital major cardiovascular events compared to a 2019 historical control.
Synapse has enriched 10 related papers. Consider them for comparative context: